Ambrose Healthcare Ltd (Ambrose Healthcare), a specialist pharmaceutical company in rare diseases and hospital care, has established its global headquarters in Wrexham, Wales.
The move enables Ambrose Healthcare to benefit from the vibrant life sciences ecosystem in Wales that is home to over 260 life science companies, including Siemens, Ipsen and ThermoFisher Scientific.
Toby Wilson Waterworth, Chair and Chief Executive of Ambrose Healthcare said: “We’re excited to become part of an impressive network that includes clinicians, universities, medtech and diagnostic companies. This will speed our route to market and we look forward to bringing our expertise and network into the ecosystem.”
Wales’ Economy Minister, Vaughan Gething said: “I’m delighted to welcome Ambrose Healthcare to Wales. By establishing its new global headquarters in Wrexham, the company are demonstrating a vote of confidence in Wales, which is already home to a growing Life Sciences sector with hundreds of life science companies ranging from SMEs and start-ups to large blue-chip companies.
“The Welsh Government is working hard to make Wales the location of choice for inward investors. We’re committed to working in partnership with Life Sciences Hub Wales and Business Wales to encourage life science businesses to invest in Wales, and make their futures part of our future.”
About Ambrose Healthcare (www.ambrosehc.com)
Ambrose Healthcare is a specialist pharmaceutical company, developing new treatments for rare diseases, and for patients managed in hospitals and specialist care. The company has an internationally experienced leadership team with deep knowledge of the pharmaceutical industry and a track record of success. Ambrose is developing a portfolio of commercial and clinical-stage therapeutic assets through acquisition, licensing and collaborations.
Forward looking statements
While Ambrose Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Ambrose Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Ambrose Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.
For more information, please contact:
Adam Michael, Director of Communications
adam.michael@ambrosehc.com +44 7775 881 813